Who we are
Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).
On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.
Our Small Molecule Therapeutics Science
We have a deep understanding of certain biological targets and pathways that have been implicated in the inflammatory and fibrotic process, including f G-protein-couple receptor 40, or GPR40), a related receptor (G-protein-coupled receptors.
The Company is currently developing GPR84 antagonists and OXER1 antagonists. In addition to these programs, the Company continues to explore other development opportunities to add to its pipeline.